20210607_Report_534_Risankizumab_for_the_treatment_of
EN2020
32.Relatorio_Tecnico_N_547_Delamanida_TB-MDR_TB-XDR_EN
20210607_Report_533_Increasing_the_upper_age_limit_to_75_years
31.Relatorio_Tecnico_N_532_Imunoglobulina_humana_anti-hepatiteB_EN
20210106_Report531_Ruxolitinib_PrimaryMyelofibrosis-PostpolycythaemiaVeraMyelofibrosis-PostessentialThrombocythaemiaMyelofibrosis
20201119_Report526_RifapentineIsoniazid_LatentMycobacteriumTuberculosisInfection
20201119_Report525_ExclusionRifampicin_Chemoprophylaxis
20200915_Report524_EmpagliflozinandDapagliflozin_Type2_DiabetesMellitus
20200915_Report523_Orlistat_ObesePatients
20200915_Report522_Sibutramine_ObesePatients
20200915_Report519_Riociguat_ChronicThromboembolicPulmonaryHypertension
20210106_Report518_CytoreductiveSurgery_HIPEC
20201119_Report517_CytoreductiveSurgery_MalignantPeritonealMesothelioma
20200915_Report516_Newbor-Screening_CongenitalToxoplasmosis
20200915_Report515_Dolutegravir_Pregnant-HIV
20200915_Report510_Baricitinib_ActiveRheumatoidArthritis
20200915_Report509_Mirabegron_NeurogenicBladder
20200915_Report508_Antimuscarinics_NeurogenicBladder
20200915_Report507_PhotodynamicTherapy_non-melanoma_skincancer
20201119_Report506_PersonalFrequencyModulationSystem_Hearing-impairedStudents